Valuation: NFL Biosciences

Market Cap 1.05Cr 1.2Cr 97.71L 89.87L 1.69Cr 115.81Cr 1.72Cr 12Cr 4.56Cr 56Cr 4.49Cr 4.39Cr 195.98Cr P/E 2024
-9.56x
P/E 2025 -4.62x
Enterprise Value 88.99L 1.01Cr 82.67L 76.03L 1.43Cr 98Cr 1.45Cr 9.89Cr 3.86Cr 48Cr 3.8Cr 3.72Cr 165.8Cr EV / Sales 2024
3,70,592x
EV / Sales 2025 70,790x
Free-Float
85.79%
Yield 2024 *
-
Yield 2025 -
1 week-1.31%
Current month-4.60%
1 month-4.05%
3 months-20.04%
6 months-49.08%
Current year-29.54%
1 week 0.83
Extreme 0.83
0.85
1 month 0.83
Extreme 0.83
0.92
Current year 0.8
Extreme 0.8
1.85
1 year 0.8
Extreme 0.8
1.85
3 years 0.8
Extreme 0.8
3.31
5 years 0.55
Extreme 0.548
5
10 years 0.55
Extreme 0.548
5
Manager TitleAgeSince
Chief Executive Officer - 17/10/2024
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman - 27/02/2023
Chairman - 17/10/2024
Director/Board Member - 19/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.31%-29.42%-68.38% 1.2Cr
+1.23%+0.35%+51.62%+87.98% 5.53TCr
+5.09%+6.24%+63.15%+62.06% 5.42TCr
+0.25%+0.55%-19.67%-15.22% 2.32TCr
+0.72%-0.05%+3.84%+409.54% 2.31TCr
-0.31%+5.41%+30.59%-3.87% 2.03TCr
-0.37%+0.71%+31.36%-31.61% 1.79TCr
+0.67%+7.83%+35.25%+557.27% 1.58TCr
-2.54%-8.73%+164.11%+289.45% 1.5TCr
+1.22%-0.05%+22.58%+182.63% 1.38TCr
Average +0.55%+0.51%+35.34%+146.98% 2.39TCr
Weighted average by Cap. +1.40%+2.77%+43.66%+135.54%

Financials

2024 2025
Net sales 46 52.3 42.73 39.3 73.71 5.07T 75.03 511.01 199.32 2.47T 196.35 192.11 8.57T 188 213.76 174.65 160.63 301.24 20.7T 306.64 2.09T 814.61 10.1T 802.49 785.13 35.03T
Net income -20.81L -23.66L -19.33L -17.78L -33.34L -23Cr -33.94L -2.31Cr -90.16L -11Cr -88.82L -86.9L -39Cr -33.18L -37.73L -30.82L -28.35L -53.16L -37Cr -54.12L -3.69Cr -1.44Cr -18Cr -1.42Cr -1.39Cr -62Cr
Net Debt -20.73L -23.57L -19.25L -17.71L -33.21L -23Cr -33.8L -2.3Cr -89.8L -11Cr -88.47L -86.55L -39Cr -16.19L -18.41L -15.04L -13.84L -25.95L -18Cr -26.41L -1.8Cr -70.17L -8.7Cr -69.13L -67.63L -30Cr
Logo NFL Biosciences
NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).
Employees
4
Date Price Change Volume
23/26/23 €0.8300 0.00% 6,031
22/26/22 €0.8300 -1.78% 3,219
21/26/21 €0.8450 +1.68% 17,201
20/26/20 €0.8310 -1.19% 10,541
17/26/17 €0.8410 0.00% 8,065

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNFL Stock